Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Bolis

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Mucosal Immunology|March 6, 2024
The bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cellsHanif J Khameneh, Marco Bolis, Pedro M O Ventura, et al.
EMBO Molecular Medicine|April 19, 2015
Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expressionFloriana Centritto, Gabriela Paroni, Marco Bolis, et al.
Cell Death & Disease|July 22, 2024
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomasMichela Chiappa, Alessandra Decio, Luca Guarrera, et al.
Molecular Cell|June 9, 2023
Minor intron splicing is critical for survival of lethal prostate cancerAnke Augspach, Kyle D Drake, Luca Roma, et al.
Nature Communications|February 23, 2025
Increased ectodysplasin-A2-receptor EDA2R is a ubiquitous hallmark of aging and mediates parainflammatory responsesMaria Chiara Barbera, Luca Guarrera, Andrea David Re Cecconi, et al.
Oncogene|September 2, 2025
Integrated control of cancer stemness by σ<sub>1</sub> receptor in advanced prostate cancerGianluca Civenni, Giada Sandrini, Jessica Merulla, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 19, 2025
Mesenchymal Stromal Cell Secretome and Its Key Bioactive Metabolites Induce Long-Term Neuroprotection After Traumatic Brain Injury in MiceFrancesca Pischiutta, Francesca Tribuzio, Marta Magatti, et al.
Cell Death & Disease|February 17, 2025
Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironmentErsilia Varone, Michele Retini, Alessandro Cherubini, et al.
Cell Reports|June 15, 2025
An integrated proteomic portrait of prostate cancer progressionJichang Zhang, Keith D Rivera, Daniela Bossi, et al.
Cell Reports. Medicine|February 25, 2024
SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCASerena Germani, Andrew Tri Van Ho, Alessandro Cherubini, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Mucosal Immunology|March 6, 2024
The bacterial lysate OM-85 engages Toll-like receptors 2 and 4 triggering an immunomodulatory gene signature in human myeloid cellsHanif J Khameneh, Marco Bolis, Pedro M O Ventura, et al.
EMBO Molecular Medicine|April 19, 2015
Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expressionFloriana Centritto, Gabriela Paroni, Marco Bolis, et al.
Cell Death & Disease|July 22, 2024
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomasMichela Chiappa, Alessandra Decio, Luca Guarrera, et al.
Molecular Cell|June 9, 2023
Minor intron splicing is critical for survival of lethal prostate cancerAnke Augspach, Kyle D Drake, Luca Roma, et al.
Nature Communications|February 23, 2025
Increased ectodysplasin-A2-receptor EDA2R is a ubiquitous hallmark of aging and mediates parainflammatory responsesMaria Chiara Barbera, Luca Guarrera, Andrea David Re Cecconi, et al.
Oncogene|September 2, 2025
Integrated control of cancer stemness by σ<sub>1</sub> receptor in advanced prostate cancerGianluca Civenni, Giada Sandrini, Jessica Merulla, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 19, 2025
Mesenchymal Stromal Cell Secretome and Its Key Bioactive Metabolites Induce Long-Term Neuroprotection After Traumatic Brain Injury in MiceFrancesca Pischiutta, Francesca Tribuzio, Marta Magatti, et al.
Cell Death & Disease|February 17, 2025
Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironmentErsilia Varone, Michele Retini, Alessandro Cherubini, et al.
Cell Reports|June 15, 2025
An integrated proteomic portrait of prostate cancer progressionJichang Zhang, Keith D Rivera, Daniela Bossi, et al.
Cell Reports. Medicine|February 25, 2024
SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCASerena Germani, Andrew Tri Van Ho, Alessandro Cherubini, et al.
Pageof 8